Edition:
United Kingdom

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

9.44USD
18 Apr 2019
Change (% chg)

$-0.40 (-4.07%)
Prev Close
$9.84
Open
$9.84
Day's High
$9.88
Day's Low
$9.30
Volume
104,292
Avg. Vol
70,528
52-wk High
$20.97
52-wk Low
$9.30

Barrett, Ronald 

Dr. Ronald W. Barrett, Ph.D., is an Independent Director of Concert Pharmaceuticals Inc. Dr. Barrett is the Director of the company. Dr. Barrett has served as a member of our board of directors since December 2007. Dr. Barrett is a founder of XenoPort, Inc., a public biopharmaceutical company, and has served as its Chief Executive Officer since 2001, its Chief Scientific Officer from 1999 to 2001 and as a member of its board of directors since 1999. Prior to XenoPort he held various positions at Affymax Research Institute, a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare company. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University. We believe that Dr. Barrett’s industry and board experience, including his experience as the chief executive officer of a publically traded biopharmaceutical company, makes him a key contributor to our board of directors.

Basic Compensation

Total Annual Compensation, USD 47,720
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 90,720
Fiscal Year Total, USD 138,440

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

167,720

Roger Tung

3,430,850

Marc Becker

--

Nancy Stuart

1,947,300

Lynette Herscha

--

James Cassella,

1,960,240
As Of  31 Dec 2017